| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Rogelio Apiquian, Ana Fresan, Rosa-Elena Ulloa, Camilo de la Fuente-Sandoval, Miguel Herrera-Estrella, Alejandra Vazquez, Humberto Nicolini, Shitij Kapu. Amoxapine as an atypical antipsychotic: a comparative study vs risperidone. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 30. issue 12. 2006-01-24. PMID:15956984. |
the objective of this study was to compare the antipsychotic and side effect profile of amoxapine and risperidone in a randomised assignment, standardized dosing, double-blind trial of acutely psychotic patients with schizophrenia. |
2006-01-24 |
2023-08-12 |
Not clear |
| Akio Himei, Takehiko Okamur. Evaluation of the clinical efficacy of risperidone for untreated and treated cases of schizophrenia from various aspects. Psychiatry and clinical neurosciences. vol 59. issue 5. 2006-01-20. PMID:16194258. |
evaluation of the clinical efficacy of risperidone for untreated and treated cases of schizophrenia from various aspects. |
2006-01-20 |
2023-08-12 |
Not clear |
| Akio Himei, Takehiko Okamur. Evaluation of the clinical efficacy of risperidone for untreated and treated cases of schizophrenia from various aspects. Psychiatry and clinical neurosciences. vol 59. issue 5. 2006-01-20. PMID:16194258. |
the results of this study provide evidence that risperidone has a favorable profile with regard to efficacy and safety, which makes it a suitable treatment for schizophrenia. |
2006-01-20 |
2023-08-12 |
Not clear |
| Akio Himei, Takehiko Okamur. Evaluation of the clinical efficacy of risperidone for untreated and treated cases of schizophrenia from various aspects. Psychiatry and clinical neurosciences. vol 59. issue 5. 2006-01-20. PMID:16194258. |
risperidone therapy at the earliest possible stage shows optimal improvement in schizophrenia. |
2006-01-20 |
2023-08-12 |
Not clear |
| W Wolfgang Fleischhacker, Jonathan Rabinowitz, Georg Kemmler, Mariëlle Eerdekens, Angelika Mehner. Perceived functioning, well-being and psychiatric symptoms in patients with stable schizophrenia treated with long-acting risperidone for 1 year. The British journal of psychiatry : the journal of mental science. vol 187. 2006-01-10. PMID:16055823. |
perceived functioning, well-being and psychiatric symptoms in patients with stable schizophrenia treated with long-acting risperidone for 1 year. |
2006-01-10 |
2023-08-12 |
Not clear |
| Karsten Wolf, Reinhard Mass, Falk Kiefer, Kirsten Eckert, Alexandra V Stritzky, Christian Haasen, Klaus Wiedemann, Dieter Nabe. The influence of olanzapine versus risperidone on facial expression of emotions in schizophrenia--preliminary results of a facial electromyogram study. Journal of clinical psychopharmacology. vol 25. issue 3. 2005-12-30. PMID:15876912. |
the influence of olanzapine versus risperidone on facial expression of emotions in schizophrenia--preliminary results of a facial electromyogram study. |
2005-12-30 |
2023-08-12 |
Not clear |
| Concetta D'Arrigo, Gaetana Migliardi, Vincenza Santoro, Letterio Morgante, Maria Rosaria Muscatello, Maria Ancione, Edoardo Spin. Effect of fluvoxamine on plasma risperidone concentrations in patients with schizophrenia. Pharmacological research. vol 52. issue 6. 2005-12-22. PMID:16226034. |
effect of fluvoxamine on plasma risperidone concentrations in patients with schizophrenia. |
2005-12-22 |
2023-08-12 |
human |
| E Parellada, R Andrezina, V Milanova, P Glue, M Masiak, M St John Turner, R Medori, W Gaebe. Patients in the early phases of schizophrenia and schizoaffective disorders effectively treated with risperidone long-acting injectable. Journal of psychopharmacology (Oxford, England). vol 19. issue 5 Suppl. 2005-12-15. PMID:16144781. |
patients in the early phases of schizophrenia and schizoaffective disorders effectively treated with risperidone long-acting injectable. |
2005-12-15 |
2023-08-12 |
Not clear |
| E Parellada, R Andrezina, V Milanova, P Glue, M Masiak, M St John Turner, R Medori, W Gaebe. Patients in the early phases of schizophrenia and schizoaffective disorders effectively treated with risperidone long-acting injectable. Journal of psychopharmacology (Oxford, England). vol 19. issue 5 Suppl. 2005-12-15. PMID:16144781. |
the efficacy and safety of risperidone long-acting injectable (rlai) was investigated in patients in the early phases of schizophrenia and schizoaffective disorders (< or = 3 years). |
2005-12-15 |
2023-08-12 |
Not clear |
| M Gastpar, M Masiak, M A Latif, S Frazzingaro, R Medori, E-R Lomberti. Sustained improvement of clinical outcome with risperidone long-acting injectable in psychotic patients previously treated with olanzapine. Journal of psychopharmacology (Oxford, England). vol 19. issue 5 Suppl. 2005-12-15. PMID:16144784. |
the efficacy and tolerability of risperidone long-acting injectable were investigated in patients with schizophrenia or other psychotic disorders who had previously been symptomatically stable on olanzapine treatment. |
2005-12-15 |
2023-08-12 |
Not clear |
| M Gastpar, M Masiak, M A Latif, S Frazzingaro, R Medori, E-R Lomberti. Sustained improvement of clinical outcome with risperidone long-acting injectable in psychotic patients previously treated with olanzapine. Journal of psychopharmacology (Oxford, England). vol 19. issue 5 Suppl. 2005-12-15. PMID:16144784. |
this open study suggests that risperidone long-acting injectable produces symptomatic improvement in schizophrenia patients previously considered symptomatically stable with olanzapine, along with improvement in movement disorders. |
2005-12-15 |
2023-08-12 |
Not clear |
| Jorge Rovner, Sheila Assunção, Pedro Gargoloff, Hernan Silva Ibarra, Jaime Aguilar Gasca, Erick Landa Fournais, Pablo Adan, Nestor J Andrades, Yulia Dyachkov. [Functional status and quality of life in Latin American outpatients with schizophrenia treated with atypical or typical antipsychotics: outcomes of the 12 months schizophrenia outpatient health outcomes (IC-SOHO) Study]. Vertex (Buenos Aires, Argentina). vol 16. issue 63. 2005-12-15. PMID:16220148. |
functional status and quality of life outcomes in latin american outpatients with schizophrenia were compared after 12 months of monotherapy treatment with olanzapine, risperidone or typical antipsychotics. |
2005-12-15 |
2023-08-12 |
Not clear |
| Norbert Müller, Michael Riedel, Markus J Schwarz, Rolf R Enge. Clinical effects of COX-2 inhibitors on cognition in schizophrenia. European archives of psychiatry and clinical neuroscience. vol 255. issue 2. 2005-12-07. PMID:15549344. |
data from a schizophrenia study were reevaluated under the aspect whether an effect on the positive and negative syndrome scale (panss) factor cognition can be observed during therapy with the cox-2 inhibitor celecoxib add on to risperidone in comparison to riperidone alone. |
2005-12-07 |
2023-08-12 |
Not clear |
| Robert R Conley, Deanna L Kelly, Matthew W Nelson, Charles M Richardson, Stephanie Feldman, Rhonda Benham, Patricia Steiner, Yang Yu, Ijaz Khan, Ron McMullen, Elizabeth Gale, Marie Mackowick, Raymond C Lov. Risperidone, quetiapine, and fluphenazine in the treatment of patients with therapy-refractory schizophrenia. Clinical neuropharmacology. vol 28. issue 4. 2005-12-07. PMID:16062094. |
risperidone, quetiapine, and fluphenazine in the treatment of patients with therapy-refractory schizophrenia. |
2005-12-07 |
2023-08-12 |
human |
| Robert R Conley, Deanna L Kelly, Matthew W Nelson, Charles M Richardson, Stephanie Feldman, Rhonda Benham, Patricia Steiner, Yang Yu, Ijaz Khan, Ron McMullen, Elizabeth Gale, Marie Mackowick, Raymond C Lov. Risperidone, quetiapine, and fluphenazine in the treatment of patients with therapy-refractory schizophrenia. Clinical neuropharmacology. vol 28. issue 4. 2005-12-07. PMID:16062094. |
this 12-week, double-blind study evaluated the effectiveness of risperidone (4 mg/day), quetiapine (400 mg/day), or fluphenazine (12.5 mg/day) in a stringently defined treatment-resistant population of people with schizophrenia. |
2005-12-07 |
2023-08-12 |
human |
| Philippos Gourzis, Panagiotis Polychronopoulos, Spiridon Papapetropoulos, Konstantinos Assimakopoulos, Andreas A Argyriou, Stavroula Berati. Quetiapine in the treatment of focal tardive dystonia induced by other atypical antipsychotics: a report of 2 cases. Clinical neuropharmacology. vol 28. issue 4. 2005-12-07. PMID:16062102. |
the authors report 2 patients with schizophrenia who developed focal tardive dystonia secondary to treatment with atypical antipsychotics (risperidone, olanzapine). |
2005-12-07 |
2023-08-12 |
Not clear |
| Frank-Gerald Pajonk, Andreas Schreiner, Stefan Peters, Klaus Rettig, Detlef Degner, Eckart Rüthe. Risperidone: an open-label, observational study of the efficacy, tolerability, and prescribing behavior in acutely exacerbated patients with schizophrenia. Journal of clinical psychopharmacology. vol 25. issue 4. 2005-12-06. PMID:16012270. |
risperidone: an open-label, observational study of the efficacy, tolerability, and prescribing behavior in acutely exacerbated patients with schizophrenia. |
2005-12-06 |
2023-08-12 |
Not clear |
| Frank-Gerald Pajonk, Andreas Schreiner, Stefan Peters, Klaus Rettig, Detlef Degner, Eckart Rüthe. Risperidone: an open-label, observational study of the efficacy, tolerability, and prescribing behavior in acutely exacerbated patients with schizophrenia. Journal of clinical psychopharmacology. vol 25. issue 4. 2005-12-06. PMID:16012270. |
this study evaluated treatment practices over 7 years of initial treatment with oral risperidone in acutely exacerbated patients with schizophrenia and in a subgroup of highly agitated, tense, and aggressive patients. |
2005-12-06 |
2023-08-12 |
Not clear |
| Ilya Lipkovich, David Baron, John Houston, Jonna Ahl, Matthew Rotell. Flexible-dose clinical trials: predictors and outcomes of antipsychotic dose adjustments. Journal of clinical psychopharmacology. vol 25. issue 4. 2005-12-06. PMID:16012284. |
this was a post hoc analysis of 3 flexible-dosed olanzapine studies: acutely ill bipolar i patients with an index manic episode (n = 452) who received olanzapine (5-20 mg/d) or haloperidol (3-15 mg/d); acutely ill patients with schizophrenia (n = 339) who received olanzapine (10-20 mg/d) or risperidone (4-12 mg/d) for 28 weeks; and remitted bipolar i patients (n = 361) who received olanzapine (5-20 mg/d) or placebo for 48 weeks. |
2005-12-06 |
2023-08-12 |
Not clear |
| Jan Volavka, Karen A Nolan, Linda Kline, Pal Czobor, Leslie Citrome, Brian Sheitman, Jean-Pierre Lindenmayer, Joseph McEvoy, Jeffrey A Lieberma. Efficacy of clozapine, olanzapine, risperidone, and haloperidol in schizophrenia and schizoaffective disorder assessed with nurses observation scale for inpatient evaluation. Schizophrenia research. vol 76. issue 1. 2005-11-30. PMID:15927808. |
efficacy of clozapine, olanzapine, risperidone, and haloperidol in schizophrenia and schizoaffective disorder assessed with nurses observation scale for inpatient evaluation. |
2005-11-30 |
2023-08-12 |
Not clear |